2,5-二氨基-3-甲基吡啶 | 106070-58-0

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2,5-二氨基-3-甲基吡啶
• 中文别名: 3-甲基吡啶-2,5-二胺
• 英文名称: 2,5-diamino-3-methylpyridine
• 英文别名: 3-Methylpyridine-2,5-diamine
• CAS: 106070-58-0
• 化学式: C₆H₉N₃
• 分子量: 123.158
• InChiKey: NHGCVIIPNIZFJM-UHFFFAOYSA-N

物化性质

• 沸点：
  219.27°C (rough estimate)
• 密度：
  1.0161 (rough estimate)

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  64.9
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2933399090

SDS

Name:	2 5-Diamino-3-Picoline Material Safety Data Sheet
Synonym:	None Known
CAS:	106070-58-0

Section 1 - Chemical Product MSDS Name:2 5-Diamino-3-Picoline Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
106070-58-0	2,5-Diamino-3-Picoline	ca. 100	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.Hygroscopic (absorbs moisture from the air).
Potential Health Effects
Eye:
Causes eye irritation. May cause chemical conjunctivitis.
Skin:
Causes skin irritation.
Ingestion:
May cause gastrointestinal irritation with nausea, vomiting and diarrhea. The toxicological properties of this substance have not been fully investigated.
Inhalation:
Causes respiratory tract irritation. The toxicological properties of this substance have not been fully investigated. Can produce delayed pulmonary edema.
Chronic:
Effects may be delayed.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid. Do NOT use mouth-to-mouth resuscitation.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Minimize dust generation and accumulation. Avoid breathing dust, vapor, mist, or gas. Avoid contact with eyes, skin, and clothing.
Keep container tightly closed. Avoid ingestion and inhalation. Use with adequate ventilation. Wash clothing before reuse.
Storage:
Store in a cool, dry place. Store in a tightly closed container.
Store protected from moisture.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 106070-58-0: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: Not available.
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C6H9N3
Molecular Weight: 123

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Dust generation, excess heat, exposure to moist air or water.
Incompatibilities with Other Materials:
Moisture.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Will not occur.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 106070-58-0 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
2,5-Diamino-3-Picoline - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 106070-58-0: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 106070-58-0 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 106070-58-0 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2,5-二氨基-3-甲基吡啶 在 吡啶 、 palladium 10% on activated carbon 、 氢气 、 三乙胺 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 、 水 、 异丙醇 为溶剂， 反应 89.5h， 生成 5′-O-(4,4′-dimethoxytrityl)-3′-O-[2-cyanoethoxy(diisopropylamino)phosphino]-1β-[2-chloro-4-N-((2-phenoxyacetamide-3-methylp)yridin-5-yl)-pyrimidin-5-yl]-1′,2′-dideoxy-D-ribofuranose
  参考文献：
  名称：

  基于嘧啶骨架的C-核苷类似物的合成，用于形成具有CG错配位点的反平行型三链体DNA

  摘要：

  三重DNA形成方法作为基因靶向剂是有吸引力的工具。使用基于C-核苷的人工核苷类似物，可以在双链体DNA的特定区域中形成稳定且选择性的三链体DNA，并且其生物技术应用将大大扩展。在这项研究中，我们设计和合成了基于嘧啶骨架，3Me AP-d（Y-Cl）和3Me的新型C-核苷类似物AP-d（YH），能够识别天然核苷无法识别的CG错配位点。将它们掺入寡核苷酸后，通过凝胶位移测定法评估其三链体形成能力。尽管它只是一个序列，即3'-GZG-5'序列，但与以前的核苷类似物相比，CG错配位点识别的稳定性大大提高了。

  DOI：

  10.1016/j.bmc.2020.115782
• 作为产物：
  描述：

  2-氨基-3-甲基-5-硝基吡啶 在 铁粉 、 氯化铵 作用下， 以 乙醇 、 水 为溶剂， 反应 3.0h， 生成 2,5-二氨基-3-甲基吡啶
  参考文献：
  名称：

  [EN] N- (6-AMINOPYRIDIN-3-YL) -3- (SULFONAMIDO) BENZAMIDE DERIVATIVES AS B-RAF INHIBITORS FOR THE TREATMENT OF CANCER
  [FR] DÉRIVÉS DE N-(6-AMINOPYRIDIN-3-YL)-3-(SULFONAMIDO) BENZAMIDE COMME INHIBITEURS DE B-RAF POUR LE TRAITEMENT DU CANCER

  摘要：

  式(I)的化合物对于抑制Raf激酶是有用的。本文揭示了利用式(I)的化合物及其立体异构体和药学上可接受的盐，在哺乳动物细胞中进行体外、体内和体内诊断、预防或治疗这些疾病，或相关病理条件的方法。

  公开号：

  WO2009111280A1

文献信息

• [EN] PYRROLOPYRIMIDINE COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS PYRROLOPYRIMIDINIQUES ET LEURS UTILISATIONS
  申请人：HUTCHISON MEDIPHARMA LTD

  公开号：WO2012022045A1

  公开（公告）日：2012-02-23

  The present invention provides pyrrolopyrimidine compounds and methods of use therefor. In particular, the invention provides certain pyrrolopyrimidine compounds having the activity of inhibiting JAK kinases. The invention also provides the pharmaceutical compositions containing these pyrrolopyrimidine compounds and use of these compounds in the treatment of inflammatory diseases and cancer.

  本发明提供吡咯吡嘧啶化合物及其使用方法。具体而言，本发明提供具有抑制JAK激酶活性的特定吡咯吡嘧啶化合物。本发明还提供含有这些吡咯吡嘧啶化合物的药物组合物，并将这些化合物用于治疗炎症性疾病和癌症。
• Aminopyridinyl-Pseudodeoxycytidine Derivatives Selectively Stabilize Antiparallel Triplex DNA with Multiple CG Inversion Sites
  作者：Hidenori Okamura、Yosuke Taniguchi、Shigeki Sasaki

  DOI：10.1002/anie.201606136

  日期：2016.9.26

  The sequence‐specific formation of triplex DNA offers a potential basis for genome‐targeting technologies. In an antiparallel triplex DNA, the sequence‐specificity is established by the formation of specific base triplets (G−GC, A−AT, and T−AT) between a triplex‐forming oligonucleotide (TFO) and a duplex DNA. However, there are no natural nucleosides that can selectively recognize the inverted CG and

  三链体DNA的序列特异性形成为基因组靶向技术提供了潜在的基础。在反平行三链体DNA中，通过在三链体形成寡核苷酸（TFO）和双链体DNA之间形成特定的碱基三联体（G-GC，A-AT和T-AT）来建立序列特异性。但是，没有天然的核苷可以选择性识别反向的CG和TA碱基对。因此，识别CG和TA反转位点以形成稳定的三链DNA一直是三链形成技术的长期目标。现在，我们描述伪脱氧胞苷（ΨdC）衍生物的设计和合成，以选择性识别CG碱基对以扩大三链体形成序列。带有氨基吡啶的ΨdC衍生物在所有相邻碱基环境中均表现出对CG碱基对的高选择性和亲和力。值得注意的是，3-甲基-2-氨基吡啶基-pydC（我AP-ΨdC）形成有包含四个CG反转位点hTERT基因基因的启动子序列的稳定三重，并且有效地抑制其转录在人癌细胞中。因此，我AP-ΨdC有望作为形成三链体的寡核苷酸用于各种基因组靶向应用的新起点。
• [EN] PIPERIDIN-1- YL-N-PYRYDI NE-3-YL-2-OXOACET AM IDE DERIVATIVES USEFUL FOR THE TREATMENT OF MTAP-DEFICIENT AND/OR MT A-ACCUMULATING CANCERS<br/>[FR] DÉRIVÉS DE PIPÉRIDIN-1-YL-N-PYRYDINE-3-YL-2-OXO-ACÉTAMIDE UTILES POUR LE TRAITEMENT DE CANCERS DÉFICIENTS EN MTAP ET/OU ACCUMULANT MTA
  申请人：TANGO THERAPEUTICS INC

  公开号：WO2022026892A1

  公开（公告）日：2022-02-03

  Compounds are provided according to Formula (I) and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1, R2, R3, R4, R6, R7, R8 and n are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.

  根据公式（I）提供化合物及其药用盐，以及药物组合物；其中R1、R2、R3、R4、R6、R7、R8和n的定义如本文所述。本发明的化合物被认为对预防和治疗各种疾病条件有用。
• AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH
  申请人：Bahmanyar Sogole

  公开号：US20100093698A1

  公开（公告）日：2010-04-15

  Provided herein are Heteroaryl Compounds of formula (I): wherein R 1 and R 2 are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing inflammatory conditions or cancer, and conditions treatable or preventable by inhibition of a kinase or a kinase pathway comprising administering an effective amount of a Heteroaryl Compound to a subject in need thereof.

  本文提供了公式（I）的杂环芳基化合物：其中R1和R2如本文所定义，包含有效量杂环芳基化合物的组合物，以及用于治疗或预防炎症性疾病或癌症的方法，以及通过抑制激酶或激酶途径治疗或预防的疾病，包括向需要的受试者施用有效量杂环芳基化合物。
• Substituted Triazole Derivatives As Oxytocin Antagonists
  申请人：Brown Alan Daniel

  公开号：US20080214622A1

  公开（公告）日：2008-09-04

  The present invention relates to a class of substituted triazoles of formula (I) with activity as oxytocin antagonists, uses thereof, processes for the preparation thereof and compositions containing said inhibitors. These inhibitors have utility in a variety of therapeutic areas including sexual dysfunction, particularly premature ejaculation (P.E.).

  本发明涉及一类式（I）的取代三唑化合物，具有催产素拮抗剂活性，其用途、制备工艺及含有该抑制剂的组合物。这些抑制剂在多种治疗领域中具有实用价值，包括性功能障碍，尤其是早泄（P.E.）。